Strides Arcolab surges on receiving USFDA approval for Benzonatate softgel capsules

31 Jul 2015 Evaluate

Strides Arcolab is currently trading at Rs. 1273.95, up by 16.05 points or 1.28% from its previous closing of Rs. 1257.90 on the BSE.

The scrip opened at Rs. 1265.05 and has touched a high and low of Rs. 1279.90 and Rs. 1265.05 respectively. So far 33697 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1335.45 on 17-Jul-2015 and a 52 week low of Rs. 625.10 on 26-Sep-2014.

Last one week high and low of the scrip stood at Rs. 1297.00 and Rs. 1234.05 respectively. The current market cap of the company is Rs. 7590.34 crore.

The promoters holding in the company stood at 27.65% while Institutions and Non-Institutions held 45.94% and 26.41% respectively.

Strides Arcolab has received approval from the United State Food & Drug Administration (USFDA) for Benzonatate capsules USP, 100 mg and 200 mg. The product will be manufactured at the company’s Oral Dosage facility at Bangalore and marketed by strides in the US Market. The product will be launched immediately. The US market for Benzonatate is approximately $41 million.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

 

Strides Pharma Scien Share Price

793.60 -2.60 (-0.33%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×